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Editorial on the Research Topic
Newborn Screening for Inborn Errors of Metabolism
Inborn errors of metabolism (IEMs) are a large group of debilitating hereditary disorders,
commonly manifesting during infancy and early childhood (Mak et al., 2013). They are categorized
mainly according to the chemical nature of the characteristic metabolites accumulating in each
disease. Major categories include aminoacidopathies, organic acid disorders, lysosomal storage
disorders, fatty acid oxidation defects, and many others. Collectively, they constitute over 1,000
individual genetic disorders resulting in substantial societal and financial burdens overloading
families, communities, and health care authorities worldwide (Péntek et al., 2016; Zeltner et al.,
2017). These burdens are only expected to go higher under the current pandemic situation
necessitating better planning for a better care of such disorders in the future (Elmonem et al., 2020).
Historically, the concept of newborn screening (NBS) was first applied to the amino acid
metabolic disorder phenylketonuria using a simple bacterial inhibition assay to detect high
phenylalanine concentrations in dried blood spots almost 60 years ago (Guthrie and Susi, 1963).
Since then, the technologies used, and the metabolites discovered for the newborn screening
of various IEMs have significantly advanced. Furthermore, with the recent discovery of novel
therapeutic modalities for many inborn errors of metabolism, such as enzyme replacement
therapies and substrate reduction therapies, the importance of newborn screening for these
disorders is gainingmore momentum. Especially that for most inborn errors, the earlier the specific
therapy starts, the better the prognosis will be (Selim et al., 2014). Currently, hundreds of regional
and national health care authorities all over the world have running programmes for the newborn
screening of IEMs, which usually vary widely depending on the disease spectrum and financial
limitations of each country.
Similar to the beginnings of NBS, metabolite-based screening is still the dominant form in all
running programmes worldwide for the detection of various IEMs today. Almost two decades ago,
tandem mass spectrometry (TMS) based techniques have revolutionized the metabolite screening
for IEM allowing the multiplex screening of various metabolites and various diseases in the same
run using the same sample with the added benefits of cost-effectiveness, high throughput, and low
false positive and false negative rates (Pollitt et al., 1997; Rashed et al., 1997). This allowed the
widespread use of TMS in the newborn screening for IEMs even in many developing countries
in spite of their financial limitations (Hassan et al., 2016; Borrajo, 2021). However, the numbers
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of disorders that can be evaluated simultaneously by the same
mass spectrometric methodology are limited. Furthermore, the
sensitivity and specificity of the multiplex method toward various
metabolites and the stability of these metabolites are not equal
favoring the diagnostic outcomes of certain diseases over others.
Next generation sequencing in the form of whole exome and
whole genome analysis is now being proposed strongly as a
potential alternative for mass spectrometric newborn screening
for IEMs (Narravula et al., 2017; Adhikari et al., 2020; Wojcik
et al., 2021). These techniques have the advantages of high
throughput, high accuracy and potentially being able to detect all
types of genetic disorders even beyond the scope of inborn errors
of metabolism with almost identical sensitivity and specificity.
The transition to genetic diagnosis in newborn screening
requires major logistical and ethical hurdles to be overcome.
However, the major limiting factors include data interpretation
dilemmas, which will be required to handle variants of uncertain
significance in each individual, and the current relatively high
cost of such techniques. Interestingly, with gaining experience
through an actual newborn screening program, it is expected
that variants of uncertain significance will be mostly reclassified
into either benign/likely benign or pathogenic/likely pathogenic
in the span of a few years. Furthermore, the running costs of
genetic diagnostics are getting lower and lower by the day giving
hope to the application of a universal screening technology for all
hereditary disorders and leaving the role of metabolite analysis
and biochemical assays for the second-tier and confirmatory
tests. It seems like a second revolution in newborn screening for
the detection of inborn errors of metabolism is approaching.
This Research Topic collection includes 13 articles from
several countries applying newborn screening and genetic
diagnosis for the detection of IEMs. Wang Y. et al. have
discussed an important but commonly overlooked cause of
sample contamination in newborn screening by TMS, which
is the injection syringe. They summarized their experience in
the Nanjing NBS programme in eastern China and the steps
they performed to reach the actual cause of contamination.
They further described how to treat and guard against the
contamination recurrence in the future. Similarly, Peng et al.
have provided valuable data about the important role the timing
of sampling could play in impacting screening performances
of mass spectrometric NBS programmes. They compared three
sampling times: early (12–23 h), standard (24–48 h), and late
(49–168 h) in a large population-based newborn cohort from
California, USA. They found a significantly higher false positive
rate for phenylketonuria testing when age at blood collection was
between 12 and 23 h. Other analytes were also impacted in the
early and late sampling groups.
Several studies included in this article collection have
summarized the outcomes of different running NBS programmes
in different countries. Maguolo et al. described their experience
in the diagnosis, management and follow up of biotinidase
deficiency patients showing key strategies and unsolved questions
of the management of their patients in Verona, Italy. The study
concluded that NBS introduction for biotinidase deficiency in
Verona had a dramatic impact on its diagnosis and the incidence
has increased significantly compared to other areas in Italy.
Remec, Urh Groselj et al. described patients with very long-chain
acyl-CoA dehydrogenase deficiency (VLCAD) diagnosed mainly
through a recent expanded NBS programme by TMS that started
in Slovenia in 2018. The study further investigated the genetic
background of all screen positive newborns and reported four
novel pathogenic variants in the ACADVL gene. Wang X. et al.
reported on the diagnostic outcomes of their NBS programme of
congenital adrenal hyperplasia in Nanjing, China over the period
2000–2019. During this period, over one million newborns were
screened, and 62 patients were diagnosed with 21-hydroxylase
deficiency with an incidence of 1/19,858 live birth. The study
further reported 18 different pathogenic variants in the CYP21A2
gene and commented on their genotype-phenotype correlations.
A broader scope of the NBS programme for all detectable IEMs
by TMS in Liuzhou, Southern China was reported by Tan
et al. Hotspot mutations in PAH gene (Phenylketonuria), IVD
gene (Isovaleric academia), ACADS gene (short chain Acyl-CoA
dehydrogenase deficiency), SLC22A5 gene (Creatine deficiency)
and GCDH gene (Glutaric aciduria type-I) were reported.
Stinton et al. conducted a systematic review of test accuracy
of acylcarnitines measurement in dried blood spots by TMS
for the newborn screening of long-chain 3-hydroxyacyl-
CoA dehydrogenase deficiency (LCHAD) and mitochondrial
trifunctional protein deficiency (MTP). They showed that the
positive predictive value of the test in the literature varied
considerably, while sensitivity, specificity, and negative predictive
value could not be calculated as the negatively screened newborns
were not followed-up. Koracin et al. further evaluated the status
of newborn screening for IEMs in South-Eastern-Europe through
conducting detailed surveys about the services provided for the
screening of IEMs in each of the 12 participating countries. Two
consecutive surveys were conducted; the first was in 2013/2014,
while the second was in 2020. The study concluded that the
current status of NBS programs in South-Eastern-Europe is very
variable and is still underdeveloped.
Pure genetic studies reporting novel phenotypes and novel
genetic variants in families complaining of D-Bifunctional
protein deficiency and sulfite oxidase deficiency were
reported by Chen et al. and Zhao et al., respectively. Zeng
et al. further evaluated the screening of SLC25A13 genetic
variants for the detection of citrin deficiency. In their
study, a real-time PCR-based multicolor melting curve
analysis was developed to detect the four most prevalent
mutations in SLC25A13 in the Chinese Han population in
one closed-tube reaction. The melting curve analysis identified
previously diagnosed patients accurately and determined
the carrier frequency of the four common pathogenic
variants in SLC25A13 in 5,332 healthy newborns, which
was surprisingly high.
Finally, the promise of replacing the metabolite-based
newborn screening approach with the genetic-based approach
has been extensively discussed in two reviews: Remec, Trebusak
Podkrajsek et al. and Woerner et al. The first review focused
on the technical feasibility, economic considerations, and clinical
and ethical issues of the sequencing-based techniques, while the
second review focused on the comparison between historical and
current biochemical screening methods and current and future
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genetic methods of newborn screening, as well as the practical
aspects and challenges for the use of genomic testing for NBS.
In conclusion, there is still a huge gap in most countries
between the current applied technologies for the newborn
screening of IEMs and the ideal situation, which gives every
potentially diseased newborn the right to be diagnosed as early
and as accurately as possible.We hope that with the application of
the genetic NBS methods, we will be able to address the identified
gap in the near future.
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